
Despite a Zacks Rank #3 (Hold), ResMed (RMD), a significant player in sleep-disordered breathing solutions, is highlighted as a notable momentum stock. The company exhibits strong technicals with an 'A' Momentum Style Score and 'A' VGM Score, evidenced by a 12.4% share price increase over the last four weeks. Furthermore, analyst sentiment is improving, with seven upward revisions to fiscal 2026 earnings estimates, raising the Zacks Consensus Estimate to $10.80 per share, complemented by a consistent 4.5% average earnings surprise.
ResMed (RMD) presents a compelling case for momentum investors, underscored by strong technical and forward-looking indicators despite a neutral Zacks #3 (Hold) rating. The stock has demonstrated significant recent price momentum, rising 12.4% over the past four weeks, which aligns with its top-tier 'A' grade in both the Momentum and aggregate VGM Style Scores. This performance is not purely technical; it is supported by improving analyst sentiment regarding the company's long-term earnings power. Specifically, seven analysts have revised their fiscal 2026 earnings estimates upward over the last 60 days, causing the Zacks Consensus Estimate to increase by $0.37 to $10.80 per share. Furthermore, ResMed has a consistent history of exceeding market expectations, evidenced by an average positive earnings surprise of 4.5%, suggesting operational strength and reliable execution.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.60
Ticker Sentiment